C. Ettingshausen

发表

Recombinant vs. plasma‐derived products, especially those with intact VWF, regarding inhibitor development

C. E. Ettingshausen, W. Kreuz, C. Ettingshausen, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Localization and Characterization of Mutations Within the Factor VIII Gene in a Cohort of 212 Patients with Hemophilia A

J. Oldenburg, S. Rost, R. Schwaab, 2001 .

Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children – results of a multicenter study

K. Kurnik, C. E. Ettingshausen, W. Kreuz, 2007 .

Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children--results of a multicenter studys.

K. Kurnik, C. E. Ettingshausen, W. Kreuz, 2007, Haematologica.

K. Kurnik, C. E. Ettingshausen, S. Halimeh, 2002, Blood.

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review

A. Iorio, M. Marcucci, E. Santagostino, 2010, Journal of thrombosis and haemostasis : JTH.

Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.

J. Oldenburg, T. Klingebiel, C. E. Ettingshausen, 2002, Seminars in thrombosis and hemostasis.

Replacement Therapy with Protein C Concentrate in Infants and Adolescents with Meningococcal Sepsis and Purpura Fulminans

C. E. Ettingshausen, W. Kreuz, T. Beeg, 1999, Seminars in thrombosis and hemostasis.

Role of von Willebrand factor in immune tolerance induction

C. E. Ettingshausen, W. Kreuz, C. Ettingshausen, 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Inhibitors in children with severe haemophilia A treated with recombinant and plasmatic FVIII products

L. Brandão, K. Kurnik, C. E. Ettingshausen, 2010, Hämostaseologie.

Inhibitor Development in Previously Untreated Patients with Hemophilia A and B: A Prospective 23-Year Follow-Up

J. Oldenburg, C. E. Ettingshausen, W. Kreuz, 2001 .

Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement

A. Iorio, E. Iserman, J. Oldenburg, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Symptomatic Onset of Severe Hemophilia A in Childhood is Dependent on the Presence of Prothrombotic Risk Factors

R. Junker, K. Kurnik, W. Kreuz, 2001, Thrombosis and Haemostasis.

octanate®: over 20 years of clinical experience in overcoming challenges in haemophilia A treatment

J. Oldenburg, A. Klukowska, V. Komrska, 2020, Therapeutic advances in hematology.

Inhibitors in patients with haemophilia A.

C. E. Ettingshausen, W. Kreuz, C. Ettingshausen, 2014, Thrombosis research.

The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?

C. E. Ettingshausen, W. Kreuz, C. Ettingshausen, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Abstracts from the 10th C1-inhibitor deficiency workshop

William H. Yang, A. Szilágyi, M. Margaglione, 2017, Allergy, Asthma & Clinical Immunology.

A review of immune tolerance induction with Haemate® P in haemophilia A

W. Kreuz, C. Escuriola Ettingshausen, C. Ettingshausen, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Portal vein thrombosis in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of F VIII after intramural jejunal bleeding: Successful thrombolysis under heparin therapy : Haemophilia and von Willebrand disease

C. E. Ettingshausen, W. Kreuz, I. M. Saguer, 1999 .

Spotlight on the human factor: building a foundation for the future of haemophilia A management

J. Oldenburg, K. Khair, C. Kessler, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A--an Israeli-German multicenter database study.

R. Junker, K. Kurnik, C. E. Ettingshausen, 2014, Thrombosis research.

Early long‐term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series

C. E. Ettingshausen, W. Kreuz, C. Ettingshausen, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Neonatal Sepsis: A Challenge in Hemostaseology

C. E. Ettingshausen, W. Kreuz, D. Fischer, 1999, Seminars in thrombosis and hemostasis.

New findings on inhibitor development: from registries to clinical studies

V. Jiménez‐Yuste, E. Santagostino, M. Makris, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study

C. Hermans, K. Khair, C. Négrier, 2023, Therapeutic advances in hematology.

Portal vein thrombosis in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of F VIII after intramural jejunal bleeding – Successful thrombolysis under heparin therapy

W. Kreuz, C. Escuriola Ettingshausen, I. M. Saguer, 1999, European Journal of Pediatrics.